Evidence map›Paper›PMID 32870441›Full record

ArticlePituitary2020

Cystic appearance on magnetic resonance imaging in bihormonal growth hormone and prolactin tumors in acromegaly.

Elena V Varlamov, Matthew D Wood, Joao Prola Netto, Jaclyn Thiessen, Jung Kim, Dawn Shao Ting Lim, Christine G Yedinak, Swechya Banskota, Justin S Cetas, Maria Fleseriu

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Elena V VarlamovDepartment of Medicine, Oregon Health & Science University, Portland, OR, USA.
Matthew D WoodDepartment of Pathology, Oregon Health & Science University, Portland, OR, USA.
Joao Prola NettoDepartment of Radiology, Oregon Health & Science University, Portland, OR, USA.
Jaclyn ThiessenDepartment of Radiology, Oregon Health & Science University, Portland, OR, USA.
Jung KimPituitary Center, Oregon Health & Science University, Mail Code CH8N, 3303 South Bond Ave, Portland, OR, 97239, USA.
Dawn Shao Ting LimPituitary Center, Oregon Health & Science University, Mail Code CH8N, 3303 South Bond Ave, Portland, OR, 97239, USA.
Christine G YedinakDepartment of Neurological Surgery, Oregon Health & Science University, Portland, OR, USA.
Swechya BanskotaPituitary Center, Oregon Health & Science University, Mail Code CH8N, 3303 South Bond Ave, Portland, OR, 97239, USA.
Justin S CetasDepartment of Neurological Surgery, Oregon Health & Science University, Portland, OR, USA.
Maria FleseriuDepartment of Medicine, Oregon Health & Science University, Portland, OR, USA. fleseriu@ohsu.edu.ORCID http://orcid.org/0000-0001-9284-6289
Oregon Health & Science University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate demographic, imaging and laboratory characteristics, and treatment outcomes of acromegaly patients who have bihormonal (BA) growth hormone (GH) and prolactin (PRL) immunoreactive adenomas compared to patients who have densely granulated GH adenomas (DGA) and sparsely granulated GH adenomas (SGA).

methodsRetrospective review of single-center surgically treated acromegaly patients; pathology was analyzed by a single neuropathologist using 2017 WHO criteria. Preoperative magnetic resonance imaging was assessed to evaluate tumor size, cystic component, invasion and T2 signal intensity.

resultsSeventy-seven patients; 19 BA (9 mammosomatotroph and 10 mixed GH and PRL adenomas) were compared with 30 DGA, and 28 SGA. Patients with BA were older than SGA (49.6 vs 38.5 years, p = 0.035), had a higher IGF-1 index (3.3 vs 2.3, p = 0.040) and tumors were less frequently invasive (15.8% vs 57.1%, p = 0.005). BA more frequently had a cystic component on MRI than both SGA and DGA (52.6% vs 14.3%, and 22%, p = 0.005 and 0.033, respectively). When all histological types were combined, biochemical remission postoperatively was more common in non-cystic than cystic tumors (50% vs 22.5%, p = 0.042). Somatostatin receptor ligand response rate was 66.7%, 90.9% and 37.5% in BA, DGA and SGA patients, respectively (p = 0.053).

conclusionImaging characteristics are an increasingly important adenoma behavior determinant. An adenoma cystic component may suggest that a GH adenoma is a BA. Cystic tumors exhibited lower rates of surgical remission in this series; therefore, optimized individual patient treatment is needed, as patients could be candidates for primary medical treatment.

Indexed as

AcromegalyAgedAged, 80 and overFemaleHuman Growth HormoneHumansMagnetic Resonance ImagingMaleMiddle AgedPituitary GlandPituitary NeoplasmsProlactinHuman Growth HormoneProlactinAcromegalyBihormonalGrowth hormone secreting pituitary adenomaMammosomatotrophMixed prolactin-growth secreting tumorsSomatostatin receptor ligands

Identifiers

PMID32870441
OpenAlexW3081655456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.